An open-label randomized trial of the safety and efficacy of sirolimus vs. azathioprine in living related renal allograft recipients receiving cyclosporine and prednisone combination

Clinical Transplantation

Volumn 18, Issue 1, 2004, Pages 28-38

  Machado, Paula G P ^a   Felipe, Cláudia R ^a   Hanzawa, Nilva M ^a   Park, Sung I ^a   Garcia, Riberto ^a   Alfieri, Fernando ^b   Franco, Marcelo ^a   Silva Jr , Hélio Tedesco ^a   Medina Pestana, José O ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Laboratorios Wyeth do Brasil   (Brazil)

Author keywords

Acute rejection; Clinical trial; Cyclosporine; Kidney transplantation; Sirolimus

Indexed keywords

ACICLOVIR; AXYN; AZATHIOPRINE; COTRIMOXAZOLE; CREATININE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYLPREDNISOLONE; OKT 3; PREDNISONE; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ACUTE KIDNEY TUBULE NECROSIS; ADULT; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTHRALGIA; ARTICLE; ASTHENIA; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOCAL GLOMERULOSCLEROSIS; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERTROPHY; GRAFT FAILURE; HAPLOTYPE; HEMATOLOGIC DISEASE; HEMATOMA; HEMOLYTIC UREMIC SYNDROME; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INCIDENCE; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TOXICITY; LIVING DONOR; LYMPHOCELE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MORTALITY; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OPEN STUDY; PANCYTOPENIA; PARESTHESIA; PARVOVIRUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; REFRACTORY ANEMIA; RELATIVE; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TREMOR; URINARY TRACT INFECTION; VIRUS INFECTION; WOUND HEALING IMPAIRMENT; WOUND INFECTION;

ADULT; AZATHIOPRINE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIPIDS; MALE; PREDNISONE; PROSPECTIVE STUDIES; SAFETY; SIROLIMUS;

EID: 1042280986     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2004.00113.x     Document Type: Article

References (22)

1. Kahan BD. Efficacy of SRL compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000: 356: 194.
2. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a SRL/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001: 71: 271.
3. Andoh TF, Lindsley J, Franceschini N, Bennett WM. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 1996: 62: 311.
4. Napoli KL, Wang ME, Stepkowski SM, Kahan BD. Relative tissue distributions of cyclosporine and SRL after concomitant peroral administration to the rat: evidence for pharmacokinetic interactions. Ther Drug Monit 1998: 20: 123.
5. Podder H, Stepkowski SM, Napoli KL et al. Pharmacokinetic interactions augment toxicities of SRL/cyclosporine combinations. J Am Soc Nephrol 2001: 12: 1059.
6. Halloran PF. SRL and cyclosporin for renal transplan tation. Lancet 2000: 356: 179.
7. Kaplan B, Meier-Kriesche HU, Napoli KL, Kahan BD. The effects of relative timing of SRL and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 1998: 63: 48.
8. Serkova N, Litt L, James TL et al. Evaluation of individual and combined neurotoxicity of the immunosuppressants cyclosporine and SRL by in vitro multinuclear NMR spectroscopy. J Pharmacol Exp Ther 1999: 289: 800.
9. Mahalati K, Kahan BD. Clinical pharmacokinetics of SRL. Clin Pharmacokinet 2001: 40: 573.
10. Kahan BD, Napoli KL, Kelly PA et al. Therapeutic drug monitoring of SRL: correlations with efficacy and toxicity. Clin Transplant 2000: 14: 97.
11. Kahan BD, Kramer WG. Median effect analysis of efficacy versus adverse effects of immunosuppressants. Clin Pharmacol Ther 2001: 70: 74.
12. Maleki S, GRAVES S, BECKER S et al. Therapeutic monitoring of SRL in human whole-blood samples by high-performance liquid chromatography. Clin Ther 2000: 22 (Suppl. B): B25.
13. Cockcroft DW, MH G. Prediction of creatinine clearance from serum creatinine. Nephron 1976: 16: 31.
14. MacDonald A, Scarola J, Burke JT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of SRL. Clin Ther 2000: 22 (Suppl. B): B101.
15. Moule SH, Denton RM. Multiple signaling pathways involved in the metabolic effects of insulin. Am J Cardiol 1997: 80: 41A.
16. Morrisett JD, Abdel-Fattah G, Hoogeveen R et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002: 43: 1170.
17. Groth CG, Backman L, Morales JM et al. SRL (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. SRL European Renal Transplant Study Group. Transplantation 1999: 67: 1036.
18. Kreis H, Cisterne JM, Land W et al. SRL in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000: 69: 1252.
19. Morales JM, Wramner L, Kreis H et al. SRL does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002: 2: 436.
20. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. SRL allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001: 72: 777.
21. Tedesco H, Felipe CR, Machado PG, Garcia R, Franco M, Jo M. Improved kidney graft function in patients receiving SRL, cyclosporine and steroids: the role of cyclosporine blood concentration. Transplant 2001. Chicago, IL, USA, 2001: 149.
22. MacDonald A. Improving tolerability of immunosuppressive regimens. Transplantation 2001: 72 (Suppl. 12): S105.